Investigation of Risk Factors Linked to Bloodstream Infections from Candida parapsilosis in Children and Factors Influencing Fluconazole Resistance: A 15-Year Retrospective Cohort Study - Takeaways - MDSpire

Investigation of Risk Factors Linked to Bloodstream Infections from Candida parapsilosis in Children and Factors Influencing Fluconazole Resistance: A 15-Year Retrospective Cohort Study

  • By

  • Zumrut Sahbudak Bal

  • Sema Yildirim Arslan

  • Gizem Guner Ozenen

  • Gülizar Turan

  • Kübra Cebeci

  • Ulgen Celtik

  • Gulhadiye Avcu

  • Nihal Karadas

  • Gulcihan Ozek

  • Miray Karakoyun

  • Dilek Yesim Metin

  • Suleyha Hilmioglu Polat

  • January 8, 2026

  • 0 min

Share

  • 1

    Candidemia caused by Candida parapsilosis has become increasingly prevalent, particularly in pediatric populations.

  • 2

    Fluconazole resistance in C. parapsilosis has reached alarming rates of over 40-60% in some regions, complicating treatment.

  • 3

    The study analyzed 15 years of candidemia cases at Ege University Children’s Hospital, focusing on risk factors and clinical outcomes.

  • 4

    Identifying clinical risk factors for fluconazole resistance is crucial for guiding empirical therapy in pediatric patients.

  • 5

    The research highlights the need for further studies on C. parapsilosis to improve understanding and management of candidemia.

Original Source(s)

Investigation of Risk Factors Linked to Bloodstream Infections from Candida parapsilosis in Children and Factors Influencing Fluconazole Resistance: A 15-Year Retrospective Cohort Study

  • by Zumrut Sahbudak Bal, Sema Yildirim Arslan, Gizem Guner Ozenen, Gülizar Turan, Kübra Cebeci, Ulgen Celtik, Gulhadiye Avcu, Nihal Karadas, Gulcihan Ozek, Miray Karakoyun, Dilek Yesim Metin, Suleyha Hilmioglu Polat

  • January 8, 2026

Related Content

Multimodal management of late-stage Bockenheimer disease complicated by severe anemia and coagulopathy: a case report

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

This Week’s CGT News: New FDA Genome Editing Guidance 

Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T

  • April 20, 2026

  • 6 min